Opinion in United Kingdom

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Abbey: fine time

Banco Santander-owned Abbey [ANL.L], the UK's second largest mortgage lender, is bracing itself for an expected FSA fine over its endowment mortgage complaint procedures. Although such a fine would bring the lender community more bad press, it at least embodies the welcome regulatory pressure on providers that persistently ignore mortgage endowment complaints.

Published By Datamonitor
12 Apr 2005
CommentWire
CommentWire

Abbey: FSA condemnation

The Financial Services Authority has fined Abbey [ANL.L] a record GBP2 million for "serious compliance failings" relating to its money laundering monitoring between December 2001 and April 2003. The fine will hurt Abbey as it has invested large amounts in growing its wrap platform and the success of this proposition will depend on the company's ability to gain trust from IFAs.

Published By Datamonitor
10 Dec 2003
CommentWire
CommentWire

Abbey: pay as you go

Abbey [ABBE.L], the UK's third largest mortgage lender, has raised the fee it charges on early redemption by 25%, to GBP225, and evidence suggests it is not alone among lenders in so doing. While these rate hikes are in response to higher administration costs, some lenders may be using early redemption fees to bolster margins by the back door.

Published By Datamonitor
04 May 2005
CommentWire
CommentWire

Abbey: reopening old wounds

Reports suggest the FSA will rule that Abbey must review rejected complaints over endowment mis-selling. Such a move by the UK banking watchdog would come at the worst possible time for Abbey. Abbey's new owners Banco Santander have already faced criticism over heavy job losses: the last thing the bank needs now is a public admonishment over its complaints procedures.

Published By Datamonitor
17 May 2005
CommentWire
CommentWire

Abbey: short-term solution

By cutting the payouts to its life insurance policyholders, Abbey [ABBE.L] has avoided the wrath of its investors. The move may have plugged the financial gap in the short-term but it has not solved the underlying cash flow problems faced by Abbey's life division.

Published By Datamonitor
14 Jul 2004
CommentWire
CommentWire

Abbott Laboratories: new opportunities from strategic split

The restructuring will allow each new business to develop specific strategies tailored to their distinct markets. This is particularly important for the branded pharmaceutical segment, which is forecast to see low growth over the next five years. Datamonitor expects steady growth from the new medical products company and lower risk for stockholders, itself a primary driver behind this event.

Published By Datamonitor
21 Oct 2011
Expert View
Expert View

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor
29 Jun 2010
CommentWire
CommentWire

ABC Insurance: LV= expands general insurance business

LV= has announced that its new broker division, ABC Insurance, is scheduled to launch in June 2007. The launch will add a new brand, an additional distribution channel, and a strong management team to LV='s proposition; moving it one step closer to its ambitious aim of becoming a top five UK general insurer.

Published By Datamonitor
19 Apr 2007
Expert View
Expert View

Abercrombie & Fitch: will it be another Gap story?

US casualwear brand Abercrombie & Fitch opened its first store outside North America on March 22 in London. The company plans to open flagship stores in other European cities, as well as in Japan, as it grows into a global brand. The question is whether it will achieve success with its typically American style or end up with Gap's core problem - being unable to adapt to different markets.

Published By Datamonitor
22 Mar 2007
CommentWire
CommentWire

Aberdeen Asset Management: bleak investment house

UK asset manager Aberdeen's stock keeps plummeting, and its future looks bleak. In the eyes of many investors, the company is reaping the rewards of its ill-gotten gains from the TMT bubble. Aberdeen may end up as the compensatory head that UK investors are served on a platter - and some might view this as just deserts.

Published By Datamonitor
25 Oct 2002

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.